Accelerating Your Advanced Therapeutic Discovery and Development

Founded in 2008 to provide industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) and gene editing, Applied StemCell continues to use our innovative technologies to power the discovery and development of advanced therapeutics. Our products and services enable the full spectrum of basic research to early-stage GMP manufacturing—including disease modeling, iPSC services, library construction, drug screening, and nonclinical and pre-IND studies—and our patented technologies ensure a clear IP path to commercialization.

Exclusive technology: TARGATT™ DNA knock-in platform—overcome CRISPR’s limitations with high-efficiency, site-specific knock-in of 20 kb+ DNA constructs. Express large proteins and multi-gene constructs in iPSCs, HEK203, and CHO cells for mammalian display, screening directly in mammalian cells, and more.

Products and services:

1. GMP iPSCs / MSCs cell manufacturing
• GMP iPSC services & products—reprogramming, genome editing, & Differentiation/cGMP grade iPS cell lines with drug master file (DMF) also available
• GMP MSC purification, expansion and banking
• iPSC-TARGATT™-CAR cell differentiation—Insert your CAR construct into our GMP iPSCs and differentiate into NK or T Cells for faster therapeutic development

2. iPSCs, stem cell research services & products:
• iPSC generation & characterization
• iPSC genome editing services (CRISPR, Mad7, TARGATT™, AccuBase™)—Off-the-shelf iPSC-genome edited products also available
• iPSC differentiation services, including into T Cells, NK Cells, HPCs, monocytes, RPEs, photoreceptors, endothelial cells, oligodendrocytes, NPC, neurons, astrocytes, DOPA, microglia, cardiomyocytes, and skeletal muscle)—ready-to-use iPSC-derived cells also available
• Disease modeling and drug toxicity screening (BBB testing), cytotoxicity testing
• Human iPS cell lines that have proven genome-editing/differentiation capabilities. Our cell lines are being used as a benchmark material for the development of measurement standards by NIST.

3. Animal model development and non-clinical cell therapy safety and efficacy services:
• Teratoma studies for iPSC-based therapeutic safety testing
• Non-clinical mouse cell therapy safety and efficacy studies, including dose finding, biodistribution
• CRISPR mouse gene editing services
• PBMC and CD34 mouse models (Pre-screened, pre-injected)
• Humanized mouse models

4. Antibody discovery & bioproduction:
• Antibody discovery: Leverage the benefits of TARGATT™ knock-in technology for screening and expression in mammalian cells
• Bioproduction: Bioproduction (CHO) & Transgenic Animals